Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Ophthalmology. Retina · 2020
    KKKyle KovacsAOAnton OrlinDSDolan SondhiSMStephen M. Kaminsky+2 more →SKSzilard Kiss
    PMID: 32146219PMCID: PMC7354207DOIFirst author25 citations
  2. 2
    Expert opinion on biological therapy · 2022
    KKKyle KovacsSKSzilard Kiss
    PMID: 36062410DOIFirst author23 citations
  3. 3
    The British journal of ophthalmology · 2021
    AOAnton OrlinSKSzilard KissDJDonald J D'AmicoKKKyle Kovacs
    PMID: 34656984DOISenior author9 citations

Publications

63 publications

Funding

1 grant
Completed grants (1)
  • Co-I
    AAV-Based Gene Therapy for the Long-Term Treatment of CLN2-Associated Retinal Degeneration and Prevention of Blindness in CLN2 Patients
    Daedalus Fund for Innovation (Weill Cornell) · 2021–2023BioPharma Alliance
    BP 214968-01

News mentions

1 mentionView all WCM news ↗
  • Weight-Loss Drug Linked to Lower Risk of Eye Disease in Patients with Diabetes
    February 11, 2026

    The popular diabetes and weight-loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. The findings may offer comfort to patients concerned about their eye health while taking the drug.

Mentoring

3 menteesAll publications with mentees →